214 related articles for article (PubMed ID: 14692531)
1. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
2. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
[TBL] [Abstract][Full Text] [Related]
3. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
4. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
6. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
8. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
9. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
10. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
Inagaki A; Tajima E; Uranishi M; Totani H; Asao Y; Ogura H; Masaki A; Yoshida T; Mori F; Ito A; Yano H; Ri M; Kayukawa S; Kataoka T; Kusumoto S; Ishida T; Hayami Y; Hanamura I; Komatsu H; Inagaki H; Matsuda Y; Ueda R; Iida S
Leuk Res; 2013 Dec; 37(12):1648-55. PubMed ID: 24210217
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of Pax-5 gene in human myeloma cells.
Mahmoud MS; Huang N; Nobuyoshi M; Lisukov IA; Tanaka H; Kawano MM
Blood; 1996 May; 87(10):4311-5. PubMed ID: 8639790
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
13. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
[TBL] [Abstract][Full Text] [Related]
15. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
16. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
17. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
[TBL] [Abstract][Full Text] [Related]
19. Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma.
Borson ND; Lacy MQ; Wettstein PJ
Mamm Genome; 2006 Mar; 17(3):248-56. PubMed ID: 16518692
[TBL] [Abstract][Full Text] [Related]
20. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]